Compare Inovio Pharmaceuticals Inc (INO) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs JD.Com Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while JD.Com Inc trades at $30.82 (market cap $41.80B). The key difference: JD.Com Inc is far larger — about 468.2× Inovio Pharmaceuticals Inc's market cap, and JD.Com Inc pays a 3.27% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | JD | |
|---|---|---|
Market Cap | $89.27M | $41.80B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $36.17 |
52-Week Low | $1.05 | $25.19 |
Enterprise Value | $60.28M | $27.96B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
JD.com trades at $30.60, up 3.31% with strong recent earnings beats. The stock shows bullish technical signals with moving averages supporting upside, while RSI levels indicate potential overbought conditions. Fundamentally, revenue grew to $1.31 trillion in 2025, though net income margin compressed to 1.05%. Analyst consensus remains strongly bullish with a $39.50 price target, representing significant upside potential from current levels.
JD offers attractive valuation with P/S of 0.22 and P/E of 21.75, but faces risks from Chinese regulatory environment and ongoing margin pressure. The company maintains robust cash flow generation and shareholder returns through buybacks. Near-term catalyst includes Q2 2026 earnings release with expected EPS of $0.86.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
